--- title: "Evaxion to Unveil New Phase 2 Immune Data for Personalized Cancer Vaccine EVX-01 in October and November 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/300805799.md" description: "Evaxion Biotech will present new Phase 2 immune data for its personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer meeting in November 2026. Additionally, a full three-year clinical update from the same trial will be shared at the European Society for Medical Oncology congress on October 24, 2026. This data aims to clarify the vaccine's performance as standalone therapy without anti-PD-1 treatment." datetime: "2026-10-02T13:27:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300805799.md) - [en](https://longbridge.com/en/news/300805799.md) - [zh-HK](https://longbridge.com/zh-HK/news/300805799.md) generator: "portal-rs" --- # Evaxion to Unveil New Phase 2 Immune Data for Personalized Cancer Vaccine EVX-01 in October and November 2026 Evaxion Biotech ( (EVAX) ) has issued an update. On October 2, 2026, Evaxion reported that new immune data from its phase 2 trial of EVX-01 in advanced melanoma will be presented at the Society for Immunotherapy of Cancer 2026 meeting in Phoenix in early November. The data, from patients treated with EVX-01 plus pembrolizumab, will highlight systemic immunomodulatory effects beyond vaccine-specific T-cell responses and will be showcased in both oral and poster formats. The company also noted that a full three-year clinical update from the same phase 2 trial will be delivered at the European Society for Medical Oncology congress on October 24, 2026, following previously reported two-year results showing a 75% objective response rate and durable responses in most patients. In the third year, patients received EVX-01 as stand-alone therapy, and the forthcoming readout is expected to clarify how the vaccine performs without anti-PD-1 therapy, a key data point for clinicians, partners and investors assessing EVX-01’s long-term potential and positioning in melanoma care. The most recent analyst rating on (EVAX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page. **Spark’s Take on EVAX Stock** According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral. The score is held back primarily by weak financial performance (ongoing losses, negative cash flow, and volatile small revenue) and only neutral technical setup (below longer-term moving averages). These are partially offset by constructive earnings-call updates on clinical/pipeline progress and reaffirmed runway into H2 2027, though the cash cushion remains limited and funding reliance persists. To see Spark’s full report on EVAX stock, click here. **More about Evaxion Biotech** Evaxion A/S is a Copenhagen-based clinical-stage TechBio company that develops novel immunotherapies using its proprietary AI-Immunology platform. The firm focuses on personalized and off-the-shelf cancer vaccines, as well as prophylactic vaccines for infectious and autoimmune diseases, targeting high unmet medical needs across global oncology and immunology markets. The company’s lead asset, EVX-01, is a personalized peptide-based cancer vaccine designed for first-line treatment of multiple advanced solid tumors, including advanced melanoma. Built using AI to match each patient’s unique tumor profile and immune characteristics, EVX-01 aims to elicit strong tumor-specific neoantigen responses and is being evaluated in combination with, and separate from, checkpoint inhibitor therapy. **Average Trading Volume:** 200,935 **Technical Sentiment Signal:** Sell **Current Market Cap:** $27.36M ### Related Stocks - [EVAX.US](https://longbridge.com/en/quote/EVAX.US.md) ## Related News & Research - [Evaxion reports EVX-01 induces strong immune responses in phase 2 melanoma trial](https://longbridge.com/en/news/304666419.md) - [Evaxion to Present Phase 2 Biomarker Data for Cancer Vaccine EVX-01 at SITC 2026](https://longbridge.com/en/news/304126126.md) - [New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 | EVAX Stock News](https://longbridge.com/en/news/304667725.md) - [Evaxion reports new data supporting EVX-04 vaccine for acute myeloid leukemia](https://longbridge.com/en/news/304289974.md) - [Evaxion Biotech: EVX-01 phase II showed 75% ORR and durable responses in advanced melanoma](https://longbridge.com/en/news/303611255.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**